Enterprise Value

-8.024M

Cash

80.74M

Avg Qtr Burn

-11.6M

Short % of Float

4.55%

Insider Ownership

2.87%

Institutional Own.

29.24%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DKN-01 (+/- Paclitaxel) Details
Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer

Phase 3

Update

DKN-01 + pembrolizumab Details
Cancer, Endometrial cancer

Phase 2

Data readout

DKN-01 (Bevacizumab & Chemotherapy) Details
Esophageal cancer, Cancer, Colorectal cancer

Phase 2

Update

DKN-01 (+ tislelizumab +/- CAPOX) Details
Gastroesophageal junction tumors, Cancer, Gastric cancer

Phase 2a

Data readout

FL-301 Details
Cancer, Pancreatic cancer, Gastric cancer

Phase 1

Data readout

Failed

Discontinued